Uno Studio Clinico di Fase 2b di YN001 in Adulti con Aterosclerosi Coronarica (PURIFY-TIMI 81)
Uno Studio Clinico di Fase 2b Randomizzato, Multicentrico, in Doppio Cieco, Parallelo, Controllato con Placebo per Valutare l'Efficacia e la Sicurezza di YN001 in Adulti con Aterosclerosi Coronarica
This study is designed to evaluate the efficacy and safety of intravenously administered YN001 in patients diagnosed with coronary atherosclerosis, who are receiving background therapy for cardiovascular (CV) risk factors management.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
This is a multinational, multicenter, randomized, parallel, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of intravenously administered YN001 compared with placebo in participants with coronary atherosclerosis who are receiving background therapy for CV risk factors management.
A total of 456 participants are expected to be enrolled. The study will consist of a maximum 12-week screening/Baseline period, followed by a 12-week blinded treatment period, a 30-day safety follow-up, and a long-term follow-up period through Week 96 (approximately 2 years after randomization).
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 2
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Jingmei Zhang, Master
- Numero di telefono: 0086 010 82599080
- Email: zhangjingmei@innovmedicine.com
Backup dei contatti dello studio
- Nome: Kaiqi Zong, Master
- Numero di telefono: 0086 010 82599080
- Email: zongkaiqi@innovmedicine.com
Luoghi di studio
-
-
New South Wales
-
Penrith, New South Wales, Australia, 2750
- Reclutamento
- Cannopy Clinical Research
-
Contatto:
- Karen Kaluhin, MD
- Numero di telefono: 0061 0491 276 512
- Email: kkaluhin@canopycr.com.au
-
-
Queensland
-
Brisbane, Queensland, Australia, 4064
- Reclutamento
- Core Research Group Pty Ltd.
-
Contatto:
- David Colquhou, MD
- Numero di telefono: 614-1184-2788
- Email: d.colquhoun@uq.edu.au
-
-
Victoria
-
Altona N., Victoria, Australia, 3025
- Reclutamento
- Canopy Clinical Research
-
Contatto:
- Oscar Walsh, MD
- Numero di telefono: 0061 03 9968 7601
- Email: owalsh@canopycr.com.au
-
-
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R2H 2A6
- Non ancora reclutamento
- St. Boniface Hospital
-
Contatto:
- Shuangbo Liu
- Numero di telefono: 204-237-2793
- Email: sliu@sbgh.mb.ca
-
-
Ontario
-
London, Ontario, Canada, N5A 5A5
- Non ancora reclutamento
- London Health Sciences Centre
-
Contatto:
- Habib Khan
- Numero di telefono: 519-663-3197
- Email: habib.khan@lhsc.on.ca
-
North York, Ontario, Canada, M6B 3H7
- Non ancora reclutamento
- North York Diagnostic and Cardiac Centre
-
Contatto:
- Subodh Verma, MD
- Numero di telefono: 416-436-0244
- Email: subodh.verma@unityhealth.to
-
Toronto, Ontario, Canada, M5B 1W8
- Non ancora reclutamento
- St. Michael's Hospital
-
Contatto:
- John Graham
- Numero di telefono: 416-864-6060
- Email: John.Graham@unityhealth.to
-
Vaughan, Ontario, Canada, L6A 4N9
- Non ancora reclutamento
- Cardiac Clinic
-
Contatto:
- Navneet Singh
- Numero di telefono: 905-417-3001
- Email: navneet.singh@thp.ca
-
-
Toronto
-
Toronto, Toronto, Canada, M5G 2N2
- Non ancora reclutamento
- Toronto General Hospital - University Health Network
-
Contatto:
- Jacob Udell
- Numero di telefono: 416-340-4800
- Email: jay.udell@utoronto.ca
-
-
-
-
An
-
Hefei, An, Cina, 230022
- Reclutamento
- The First Affiliated Hospital of Anhui Medical Unversity
-
Contatto:
- Jianlong Wang, MD
- Numero di telefono: 0086-13681292304
- Email: Wjlmll@sina.com
-
-
Anhui
-
Hefei, Anhui, Cina, 230001
- Reclutamento
- Anhui Provincial Hospital
-
Contatto:
- Kangyu Chen, MD
- Numero di telefono: 0086 18056005099
- Email: ustccky@126.com
-
Investigatore principale:
- Kangyu Chen, MD
-
Sub-investigatore:
- Chao Gao, MD
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Cina, 100035
- Reclutamento
- Beijing Jishuitan Hospital
-
Investigatore principale:
- Wei Liu, MD
-
Contatto:
- Qingwei Ji, MD
- Numero di telefono: 0086 18376642655
- Email: jqwl24@163.cou
-
Investigatore principale:
- Qingwei Ji, MD
-
Beijing, Beijing Municipality, Cina, 100029
- Reclutamento
- Anzhen Hospital
-
Contatto:
- Yuyang Liu, MD
- Numero di telefono: 0086 010-64456488
- Email: liuyy803803@163.com
-
Investigatore principale:
- Yuyang Liu, MD
-
Beijing, Beijing Municipality, Cina, 101100
- Non ancora reclutamento
- Beijing Luhe Hospital
-
Contatto:
- Guangyao Zhai, MD
- Numero di telefono: +86 1069543901
- Email: drzhaiguangyao@163.com
-
-
Fujian
-
Fuzhou, Fujian, Cina, 350001
- Reclutamento
- Fujian Medical University Union Hospital
-
Contatto:
- Mingfang Ye, MD
- Numero di telefono: 0086 13960818759
- Email: xieheyemingfang@163.com
-
Investigatore principale:
- Mingfang Ye, MD
-
Sub-investigatore:
- Zhaoyang Chen, MD
-
-
Gansu
-
Lanzhou, Gansu, Cina, 730030
- Reclutamento
- The Second Hospital & Clinical Medical School Lanzhou University
-
Contatto:
- Feng Bai, MD
- Numero di telefono: 0086-13609363049
- Email: baifeng@medmail.com.cn
-
-
Guangdong
-
Guangzhou, Guangdong, Cina, 510080
- Reclutamento
- Guangdong Provincial People's Hospital
-
Contatto:
- Ning Tan, MD
- Email: tanning100@126.com
-
Contatto:
- Numero di telefono: 0086-13903073651
- Email: tangning100@126.com
-
-
Heilongjiang
-
Daqing, Heilongjiang, Cina, 163316
- Reclutamento
- Daqing People's Hospital
-
Contatto:
- Shu Zhang
- Numero di telefono: +86-459-6612898
- Email: dqsrmyygcp@163.com
-
Harbin, Heilongjiang, Cina, 150001
- Reclutamento
- The First Affiliated Hospital of Harbin Medical University
-
Contatto:
- Lu Fu, MD
- Numero di telefono: 0086 137 9668 4968
- Email: fuluyidayi@163.com
-
Investigatore principale:
- Lu Fu, MD
-
Investigatore principale:
- Yongtai Gong, MD
-
-
Hubei
-
Wuhan, Hubei, Cina, 430071
- Reclutamento
- Zhongnan Hospital of Wuhan University
-
Contatto:
- Xiaorong Hu, MD
- Numero di telefono: 0086 15927681634
- Email: huzrzn@whu.edu.cn
-
Investigatore principale:
- Xiaorong Hu, MD
-
-
Hunan
-
Changsha, Hunan, Cina, 410008
- Reclutamento
- The Second Xiangya Hospital fo Central South University
-
Contatto:
- Xinqun Hu, MD
- Numero di telefono: 0086-13307313627
- Email: huxinqungs@163.com
-
-
Jilin
-
Changchun, Jilin, Cina, 130033
- Reclutamento
- The First Hospital of Jilin University
-
Investigatore principale:
- Qian Tong, MD
-
Contatto:
- Qian Tong, MD
- Numero di telefono: 0086 13074337289
- Email: tongqian187@aliyun.com
-
-
Liaoning
-
Shenyang, Liaoning, Cina, 110015
- Reclutamento
- The People's Hospital of Liaoning Province
-
Investigatore principale:
- Ying Liu, MD
-
Contatto:
- Ying Liu, MD
- Numero di telefono: 0086 13840065379
- Email: liuyingwangli@126.com
-
-
Shaanxi
-
Xi'an, Shaanxi, Cina, 710068
- Reclutamento
- Shaanxi Provincial People's Hospital
-
Contatto:
- Xiling Shou, MD
- Numero di telefono: 0086 18966700335
- Email: shouxiling@163.com
-
-
Shandong
-
Jinan, Shandong, Cina
- Reclutamento
- Central Hospital Affiliated to Shandong First Medicial University
-
Contatto:
- Guohai Su, MD
- Numero di telefono: 0086 19953193319
- Email: gttstg@163.com
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Cina, 200032
- Reclutamento
- Fudan University-Zhongshan Hospital
-
Investigatore principale:
- Junbo Ge, MD
-
Contatto:
- Junbo Ge, MD
- Numero di telefono: 021-64041990
- Email: ge.junbo@zs-hospital.sh.cn
-
Sub-investigatore:
- Yuxiang Dai, MD
-
Shanghai, Shanghai Municipality, Cina, 200001
- Reclutamento
- Renji Hospital Shanghai Jiaotong University school of medicine
-
Contatto:
- Jun Bu, MD
- Numero di telefono: 0086 13601958108
- Email: pujun310@hotmail.com
-
Investigatore principale:
- Jun Bu, MD
-
-
Sichuan
-
Chengdu, Sichuan, Cina, 610041
- Reclutamento
- West China Hospital of Sichuan University
-
Contatto:
- Yong He, MD
- Numero di telefono: 0086 18980602038
- Email: zznnyeah@163.com
-
Investigatore principale:
- Yong He, MD
-
Chengdu, Sichuan, Cina, 610072
- Reclutamento
- Sichuan Provincial People's Hospital
-
Contatto:
- Jianhong Tao, DM
- Numero di telefono: 86-189 8183 8875
- Email: Taojianhong06@medmail.com.cn
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Cina, 300211
- Reclutamento
- The Second Hospital of Tianjin Medical University
-
Contatto:
- Tong Liu, MD
- Numero di telefono: 0086 13902183163
- Email: liutongdoc@126.com
-
Investigatore principale:
- Tong Liu, MD
-
Tianjin, Tianjin Municipality, Cina, 300121
- Reclutamento
- Tianjin People's Hospital
-
Investigatore principale:
- Zhuhua Yao, MD
-
Contatto:
- Zhuhua Yao, MD
- Numero di telefono: 0086 13902199877
- Email: tjyzhpci@163.com
-
-
Zhejiang
-
Hangzhou, Zhejiang, Cina, 310006
- Reclutamento
- Zhejiang Provincial People's Hospital
-
Contatto:
- Lihong Wang, MD
- Numero di telefono: 0086-13666690598
- Email: wlhhz@hotmail.com
-
Suzhou, Zhejiang, Cina, 215006
- Reclutamento
- The First Affiliated Hospital of Soochow University
-
Contatto:
- Tingbo Jiang, MD
- Numero di telefono: 0086-18906201122
- Email: jiangtingbo6797@163.com
-
Wenzhou, Zhejiang, Cina, 325000
- Reclutamento
- The 2nd Affiliated Hospital and Yuying Children's Hospital of WMU
-
Contatto:
- lianpin Wu, MD
- Email: 198019@wzhealth.com
-
-
-
-
Alabama
-
Huntsville, Alabama, Stati Uniti, 35801-4312
- Reclutamento
- Heart Center Research, LLC
-
Contatto:
- Walter Haught, MD
- Numero di telefono: 256-519-8472
- Email: hhaught@theheartcenter.md
-
-
California
-
Covina, California, Stati Uniti, 91740
- Non ancora reclutamento
- Thrive Clinical Research Group, LLC
-
Contatto:
- Sami Hayek
- Numero di telefono: 818-280-4220
- Email: samihayek82@hotmail.com
-
Contatto:
-
Lincoln, California, Stati Uniti, 95648
- Non ancora reclutamento
- Clinical Trials Research
-
Contatto:
- Jeffrey Wayne, MD
- Numero di telefono: 916-434-8230
- Email: jwaynemd@ctrsites.com
-
Los Alamitos, California, Stati Uniti, 90720
- Non ancora reclutamento
- University of California Irvine Medical Center - Cardiovascular Center
-
Contatto:
- Arnold Seto
- Numero di telefono: 562-598-3200
- Email: arnold.seto@va.gov
-
Stanford, California, Stati Uniti, 94305-2200
- Non ancora reclutamento
- Stanford Health Care General Cardiology
-
Contatto:
- Fahim Abbasi, MD
- Numero di telefono: 650-723-6459
- Email: fahim@stanford.edu
-
Torrance, California, Stati Uniti, 90502-2006
- Reclutamento
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
-
Contatto:
- Matthew Budoff, MD
- Numero di telefono: 310-222-3641
- Email: mbudoff@lundquist.org
-
-
Florida
-
Boca Raton, Florida, Stati Uniti, 33434
- Non ancora reclutamento
- Flourish Research - Boca Raton
-
Contatto:
- Richard Goldman
- Numero di telefono: 561-756-8206
- Email: rgoldman@flourishresearch.com
-
Hialeah, Florida, Stati Uniti, 33016-1895
- Reclutamento
- New Generation of Medical Research, LLC.
-
Contatto:
- Karelia Ruiz
- Numero di telefono: 305-828-9100
- Email: kareliar@ngmresearch.com
-
St. Petersburg, Florida, Stati Uniti, 33709
- Reclutamento
- HCA Florida Heart Institute
-
Contatto:
- Robert Sanchez, MD
- Numero di telefono: 727-490-2100
- Email: robert.sanchez7@hcahealthcare.com
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30303-3049
- Non ancora reclutamento
- Emory Healthcare-Emory Heart & Vascular Center - Executive Park
-
Contatto:
- Modele Ogunniyi
- Numero di telefono: 404-616-4440
- Email: modele.ogunniyi@emory.edu
-
-
Idaho
-
Meridian, Idaho, Stati Uniti, 83642
- Non ancora reclutamento
- St. Luke's Clinic - Idaho Cardiology Associates
-
Contatto:
- Brian Nolan
- Numero di telefono: 208-322-1680
- Email: bnolan@slhs.org
-
-
Illinois
-
Springfield, Illinois, Stati Uniti, 62781
- Non ancora reclutamento
- Southern Illinois University School of Medicine
-
Contatto:
- Abdul Hafiz, MD
- Numero di telefono: 217-545-8000
- Email: ahafiz96@siumed.edu
-
-
Kansas
-
Overland Park, Kansas, Stati Uniti, 66211-1215
- Reclutamento
- Midwest Heart & Vascular Specialists, LLC
-
Contatto:
- Stephen Bloom, MD
- Numero di telefono: 913-253-3000
- Email: sbloom@kc.rr.com
-
-
Missouri
-
St Louis, Missouri, Stati Uniti, 63110-1032
- Reclutamento
- WU School of Medicine - (CAM) - Heart and Vascular Center
-
Contatto:
- Farhan Katchi, MD
- Numero di telefono: 314-362-1291
- Email: katchif@wustl.edu
-
-
North Carolina
-
Raleigh, North Carolina, Stati Uniti, 27607
- Non ancora reclutamento
- NC Heart and Vascular Research, LLC
-
Contatto:
- Mohit Pasi
- Numero di telefono: 919-784-2300
- Email: mohit.pasi2@unchealth.unc.edu
-
Winston-Salem, North Carolina, Stati Uniti, 27104-3520
- Non ancora reclutamento
- Javara Inc. - Wake Forest University Health Sciences
-
Contatto:
- Michael Shapiro, MD
- Numero di telefono: 336-713-7251
- Email: owen.spitz@javararesearch.com
-
-
Ohio
-
Cincinnati, Ohio, Stati Uniti, 45219
- Non ancora reclutamento
- The Christ Hospital
-
Contatto:
- Mark Berlacher, MD
- Numero di telefono: 513-585-1777
- Email: Mark.Berlacher@thechristhospital.com
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stati Uniti, 73135
- Non ancora reclutamento
- South Oklahoma Heart Research, LLC
-
Contatto:
- Naeem Tahirkheli
- Numero di telefono: 405-628-6865
- Email: ntahirkheli@okheart.com
-
-
Pennsylvania
-
Camp Hill, Pennsylvania, Stati Uniti, 17011
- Reclutamento
- Capital Area Research, LLC - Camp Hill
-
Contatto:
- Venkatesh Nadar, MD
- Numero di telefono: 717-695-8722
- Email: VNadar@care-research.com
-
-
Texas
-
Amarillo, Texas, Stati Uniti, 79106
- Reclutamento
- PharmaTex Research, LLC
-
Contatto:
- David Brabham
- Numero di telefono: 806-355-2581
- Email: dgbrabham@hotmail.com
-
Carrollton, Texas, Stati Uniti, 75010
- Non ancora reclutamento
- Pulse Care Heart and Vascular
-
Contatto:
- Kiran Kumar Mangalpally
- Numero di telefono: 214-407-8640
- Email: trials@stryderesearch.com
-
Tomball, Texas, Stati Uniti, 77375
- Non ancora reclutamento
- DM Clinical Research - Dallas
-
Contatto:
- Mustafa Mandviwala
- Numero di telefono: 346-550-9559
- Email: drmandviwala.ns@dmclinical.com
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Fully understands the purposes, features, and methods of the study and the possible adverse reactions, and is voluntarily willing to participate in the study, and signs the informed consent form (ICF) before performing any study-specific assessment.
- Male or female participants between 18 and 80 years (inclusive, at the time of signing the ICF).
- Participants must satisfy either of the following criteria:
1) Have clinically evident atherosclerotic CV disease (ASCVD) 2) Meet at least two of the following criteria at screening/baseline, as evidenced by:
-
A history of Type 2 diabetes requiring treatment with medication,
-
Aged > 55 years (women) or > 50 years (men),
-
2 or more of the following atherosclerosis risk factors:
-
Current cigarette smoker
-
Hypertension
-
Estimated glomerular filtration rate (eGFR) 45 to 60 ml/min/1.73m2
4. Known coronary atherosclerosis as evidenced through coronary angiography or CCTA. The following criteria must be met on the core lab CCTA interpretation for the patient to be enrolled: at least one epicardial coronary artery with a lumen stenosis of 25% to 69%, total coronary NCPV is at least 75 mm3, Detectable low-attenuation composition in one or more individual plaques.
5. Female participants must be non-pregnant and non-lactating
6. Willing and able to comply with the requirements of protocol to the best of the participant's and investigator's knowledge.
-
Exclusion Criteria:
- Prior treatment with other investigational drug(s) within 30 days or 5 half-lives, whichever is longer, prior to randomization.
- Previously received YN001.
- Any type of vaccination within 4 weeks prior to randomization, or any planned vaccination during the study treatment period
- Contraindication for CCTA
- 3 major epicardial coronary arteries with ≥ 70% or left main ≥50% stenosis.
- Acute MI that occurred within 4 weeks prior to randomization.
- PCI performed within 2 weeks prior to randomization or PCI is required or planned during study treatment based on clinical indication for revascularization.
- Clinically evident stroke or transient ischemic attack (TIA) within 6 months prior to randomization.
- Relapse and highly symptomatic arrhythmia uncontrolled by drugs within the past 3 months.
- Prior coronary artery bypass graft (CABG), aortic root surgery with coronary reimplantation, left ventricular assist device (LVAD) placement, surgical aortic valve replacement (SAVR), transcatheter aortic valve replacement (TAVR), or heart transplantation, or a plan to undergo these procedures (CABG, aortic root surgery with coronary reimplantation, LVAD placement, SAVR, TAVR, or heart transplantation) during the study.
- New York Heart Association class III or IV or last known left ventricular ejection fraction (LVEF) was <40%.
- Carotid endarterectomy or stenting, peripheral arterial revascularization, or abdominal aortic aneurysm repair within 4 weeks prior to randomization.
- History of myopathy or myositis, or susceptibility to myopathy/rhabdomyolysis (e.g., family history of hereditary myopathy, etc.).
- History of severe myalgia attributed to statin therapy or other significant concern about statin side effects.
- Known gastrointestinal ulcers, inflammatory bowel disease, or gastrointestinal/rectal bleeding within 6 months prior to randomization.
- Evidence of unresolved major diseases 2 weeks prior to randomization or planned major surgery during the study that, in the investigator's judgement, may interfere with the investigational product administration or trial assessments.
- Presenting with history of malignancy (except in participants who have been disease-free >5 years; or whose only malignancy has been basal or squamous cell skin carcinoma).
- Presence of any type of autoimmune disease.
- Allergy to multiple foods or drugs or known sensitivity to any components to be administered during dosing.
- Life expectancy is less than 1 year.
- Systolic blood pressure of ≥ 160 mmHg at final screening despite antihypertensive therapy.
- Triglycerides ≥ 400 mg/dL (4.5 mmol/L) at final screening.
- LDL-C > 100 mg/dL (2.6 mmol/L) at final screening.
- Active liver disease or hepatic dysfunction defined by any of alanine aminotransaminase (ALT), aspartate aminotransferase (AST), > 3 times upper limit of normal (ULN), or total bilirubin > 2 times ULN at final screening.
- Presence of renal dysfunction, defined by eGFR < 45 ml/min/1.73m2.
- Untreated or inadequately treated hypothyroidism.
- Poorly controlled Type 2 diabetes mellitus.
- A positive hepatitis B surface antigen (HBsAg), or positive antibody against hepatitis C virus (anti-HCV) or human immunodeficiency virus (anti-HIV), or positive treponema pallidum antibody (TP-Ab).
- Presence of any other diseases or conditions (apart from those outlined above) that, in the opinion of the investigator, would make it unsuitable for the participant to participate in this study.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Dose 1 YN001/Placebo 40mg
Dose 1 YN001/Placobo 40mg will be administrated intravenously weekly |
Dose 1 YN001/Placebo 40mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total. |
|
Sperimentale: Dose 2 YN001/Placebo 20mg
Dose 2 YN001/Placebo 20mg will be administrated intravenously weekly |
YN001/Placebo 20mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total. |
|
Comparatore placebo: Dose 3 YN001/Placebo 0mg
Dose 3 YN001/Placebo 0mg will be administrated intravenously weekly |
YN001/Placebo 0mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Relative change from baseline in coronary NCPV at Week 13
Lasso di tempo: Baseline to Week 13
|
Relative change in coronary NCPV from baseline to Week 13 as determined by coronary computed tomography angiography (CCTA) |
Baseline to Week 13
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Absolute change from baseline in carotid intima-media thickness (IMT) at Week 13
Lasso di tempo: From baseline to Week 13
|
Absolute change in carotid IMT from baseline to Week 13 as determined by carotid ultrasound. |
From baseline to Week 13
|
|
Absolute change from baseline in carotid intima-media thickness (IMT) at Week 9
Lasso di tempo: From baseline to Week 9
|
Absolute change from baseline in carotid intima-media thickness (IMT) at Week 9 |
From baseline to Week 9
|
|
Relative change from baseline in carotid intima-media thickness (IMT) at Week 13
Lasso di tempo: From baseline to Week 13
|
Relative change in carotid IMT from baseline to Week 13 as determined by carotid ultrasound |
From baseline to Week 13
|
|
Relative change in the maximum thickness and area of carotid plaque at Week 9, and Week 13
Lasso di tempo: From baseline to Week 9 and Week 13
|
Relative change in the maximum thickness and area of carotid plaque from baseline to Week 9, and Week 13 as determined by carotid ultrasound |
From baseline to Week 9 and Week 13
|
|
Relative change in coronary Percent Atheroma Volume (PAV) at Week 13
Lasso di tempo: From baseline to Week 13
|
Relative change in coronary Percent Atheroma Volume (PAV) from baseline to Week 13 as determined by CCTA |
From baseline to Week 13
|
|
Relative change in coronary Low Attenuation Plaque Volume(LAPV) at Week 13
Lasso di tempo: From baseline to week 13
|
Relative change in coronary LAPV from baseline to Week 13 as determined by CCTA. |
From baseline to week 13
|
|
Relative changes in coronary NCPV, PAV, TAV, and LAPV from baseline at 48 week
Lasso di tempo: From baseline to week 48
|
Relative changes in coronary NCPV, PAV, TAV, and LAPV from baseline to Week 48 as determined by CCTA |
From baseline to week 48
|
|
Absolute change in coronary NCPV at week 13 and week 48
Lasso di tempo: From baseline to week 13 and week 48
|
Absolute change in coronary NCPV from baseline to Week 13 and Week 48 as determined by CCTA |
From baseline to week 13 and week 48
|
|
Time to First Occurrence of Any Component of the Major Adverse Cardiac Event (MACE)
Lasso di tempo: From randomization to Week 96
|
Time to the first occurrence of the MACE, composite of CV death, myocardial infarction (MI), ischemic stroke, urgent coronary revascularization, or hospitalization for unstable angina |
From randomization to Week 96
|
|
The safety profile of YN001
Lasso di tempo: From baseline to Week 13
|
Incidence of treatment emergent adverse event (TEAE)/serious adverse event (SAE)/adverse event of special interest (AESI) |
From baseline to Week 13
|
|
Immunogenicity (ADA) analysis
Lasso di tempo: From baseline to Week 13
|
Incidence of anti-drug antibodies (ADA) formation |
From baseline to Week 13
|
|
Immunogenicity (APA) analysis
Lasso di tempo: From baseline to Week 17
|
Incidence of anti-PEG antibodies (APA) formation |
From baseline to Week 17
|
|
YN001 concentrations analysis in plasma
Lasso di tempo: From baseline to Week 13
|
Sparse blood samples will be collected, and these concentrations are intended to be pooled with other studies to develop/update pharmacometric models |
From baseline to Week 13
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Direttore dello studio: Ying Chen, PhD, Beijing Inno Medicine Co., Ltd.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- YN001-203
- IND 157167 (Identificatore di registro: Beijing Inno Medicine Co., Ltd.)
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .